Pleomorphic liposarcoma – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:36:22 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Pleomorphic liposarcoma – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Trabectedin alone versus Trabectedin with tTF-NGR combination therapy in adults with metastatic or refractory soft tissue sarcoma who failed first-line treatment https://clinicaltrials.eu/trial/study-on-trabectedin-and-ttf-ngr-for-patients-with-metastatic-or-refractory-soft-tissue-sarcoma/ Wed, 29 Apr 2026 14:59:55 +0000 https://clinicaltrials.eu/trial/study-on-trabectedin-and-ttf-ngr-for-patients-with-metastatic-or-refractory-soft-tissue-sarcoma/ This clinical trial studies a treatment for soft tissue sarcoma, a type of cancer that develops in soft tissues like muscles and fat. The study focuses on patients whose cancer has spread to other parts of the body (metastatic) or who did not respond well to previous treatments. The trial compares two treatment approaches: one using only trabectedin (a chemotherapy medication) and another combining trabectedin with tTF-NGR (an experimental drug).

The study aims to determine if adding tTF-NGR to standard trabectedin treatment helps keep the cancer under control for a longer time. Both medications are given through an intravenous infusion directly into the bloodstream. The experimental drug tTF-NGR is designed to concentrate the chemotherapy medication inside the tumor.

During the study, participants receive treatment for up to 360 days. Some patients will receive only trabectedin, while others will receive both trabectedin and tTF-NGR. Regular medical examinations and imaging tests will be performed to monitor how the cancer responds to the treatment. The study focuses on patients whose tumors show a specific characteristic called CD13 positivity, which is determined through laboratory testing.

]]> Study on the Effectiveness and Safety of INT230-6 (Vinblastine Sulfate, Cisplatin) for Adults with Metastatic Soft Tissue Sarcomas https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-int230-6-vinblastine-sulfate-cisplatin-for-adults-with-metastatic-soft-tissue-sarcomas/ Wed, 29 Apr 2026 14:59:28 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-int230-6-vinblastine-sulfate-cisplatin-for-adults-with-metastatic-soft-tissue-sarcomas/ This clinical trial is focused on studying the effectiveness and safety of a new treatment called INT230-6 for patients with certain types of soft tissue sarcomas. Soft tissue sarcomas are a group of cancers that begin in the tissues that connect, support, or surround other structures and organs of the body. The specific types of sarcomas being studied include liposarcoma, undifferentiated pleomorphic sarcoma, and leiomyosarcoma. The treatment INT230-6 is a combination of two substances, vinblastine sulfate and cisplatin, which are administered directly into the tumor.

The purpose of the study is to compare the new treatment, INT230-6, with the standard care currently used in the United States for these types of sarcomas. Participants in the study will receive either the new treatment or the standard care, which may include other medications such as Halaven, Trabectedin, or Pazopanib. The study will last for a period of up to 24 months, during which the participants’ health and response to the treatment will be closely monitored.

This trial aims to provide valuable information on whether INT230-6 can improve the overall survival of patients with these challenging types of cancer. The study will also look at the side effects and overall quality of life of the participants during the treatment period. By participating in this study, researchers hope to find more effective ways to treat soft tissue sarcomas and improve outcomes for patients in the future.

]]>